Systemic amyloidoses: What an internist should know

European Journal of Internal Medicine

Volumn 24, Issue 8, 2013, Pages 729-739

  Palladini, Giovanni ^a,b   Merlini, Giampaolo ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amyloidosis; Diagnosis; Treatment

Indexed keywords

AMYLOIDOSIS; ARTICLE; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; INTERNIST; PATHOGENESIS; PATIENT REFERRAL; PATIENT SELECTION; RARE DISEASE;

AMYLOIDOSIS; DIAGNOSIS; TREATMENT;

AMYLOIDOSIS; EARLY DIAGNOSIS; HUMANS;

EID: 84889637714     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.10.007     Document Type: Review

References (214)

1. G. Merlini, and V. Bellotti Molecular mechanisms of amyloidosis N Engl J Med 349 2003 583 596
2. R. Kyle, A. Linos, C. Beard, R. Linke, M. Gertz, and W. O'Fallon Incidence and natural history of primary systemic amyloidosis in Olmsted county, Minnesota, 1950 through 1989 Blood 79 1992 1817 1822
3. M. Gertz, M. Lacy, and A. Dispenzieri Amyloidosis Hematol Oncol Clin North Am 13 1999 1211 1233 [ix]
4. G. Merlini, and G. Palladini Amyloidosis: is a cure possible? Ann Oncol 19 2008 iv63 iv66
5. G. Palladini, and G. Merlini Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis Oncology (Williston Park) 25 2011 633 [637-638]
6. G. Merlini, A.D. Wechalekar, and G. Palladini Systemic light chain amyloidosis: an update for treating physicians Blood 121 2013 5124 5130
7. G. Merlini, and G. Palladini Differential diagnosis of monoclonal gammopathy of undetermined significance Hematology Am Soc Hematol Educ Program 2012 2012 595 603
8. J.D. Sipe, M.D. Benson, J.N. Buxbaum, S. Ikeda, G. Merlini, and M.J. Saraiva Amyloidosis NCotISo: amyloid fibril protein nomenclature: 2012 recommendations from the nomenclature committee of the international society of amyloidosis Amyloid 19 2012 167 170
9. G. Merlini, and M. Stone Dangerous small b-cell clones Blood 108 2006 2520 2530
10. R. Liao, M. Jain, P. Teller, L. Connors, S. Ngoy, and M. Skinner Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts Circulation 104 2001 1594 1597
11. G. Palladini, C. Campana, C. Klersy, A. Balduini, G. Vadacca, and V. Perfetti Serum n-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis Circulation 107 2003 2440 2445
12. G. Palladini, F. Lavatelli, P. Russo, S. Perlini, V. Perfetti, and T. Bosoni Circulating amyloidogenic free light chains and serum n-terminal natriuretic peptide type b decrease simultaneously in association with improvement of survival in al Blood 107 2006 3854 3858
13. S. Mishra, J. Guan, E. Plovie, D.C. Seldin, L.H. Connors, and G. Merlini Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish Am J Physiol Heart Circ Physiol 305 2013 H95 H103
14. R. Comenzo, Y. Zhang, C. Martinez, K. Osman, and G. Herrera The tropism of organ involvement in primary systemic amyloidosis: contributions of ig v(l) germ line gene use and clonal plasma cell burden Blood 98 2001 714 720
15. V. Perfetti, S. Casarini, G. Palladini, M. Vignarelli, C. Klersy, and M. Diegoli Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment Blood 100 2002 948 953
16. R. Abraham, S. Geyer, T. Price-Troska, C. Allmer, R. Kyle, and M. Gertz Immunoglobulin light chain variable (v) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL) Blood 101 2003 3801 3808
17. R.L. Comenzo, J. Wally, G. Kica, J. Murray, T. Ericsson, and M. Skinner Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation Br J Haematol 106 1999 744 745
18. A. Solomon, B. Frangione, and E. Franklin Bence jones proteins and light chains of immunoglobulins. Preferential association of the V lambda vi subgroup of human light chains with amyloidosis AL (lambda) J Clin Invest 70 1982 453 460
19. V. Perfetti, G. Palladini, S. Casarini, V. Navazza, P. Rognoni, and L. Obici The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44 Blood 119 2012 144 150
20. C. Rapezzi, C.C. Quarta, L. Obici, F. Perfetto, S. Longhi, and F. Salvi Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective Eur Heart J 34 2013 520 528
21. P. Westermark, K. Sletten, B. Johansson, and G.r. Cornwell Fibril in senile systemic amyloidosis is derived from normal transthyretin Proc Natl Acad Sci U S A 87 1990 2843 2845
22. L. Obici, G. Palladini, S. Giorgetti, V. Bellotti, G. Gregorini, and E. Arbustini Liver biopsy discloses a new apolipoprotein a-i hereditary amyloidosis in several unrelated Italian families Gastroenterology 126 2004 1416 1422
23. L. Obici, V. Bellotti, P. Mangione, M. Stoppini, E. Arbustini, and L. Verga The new apolipoprotein a-i variant leu(174)- > ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue n-terminal polypeptide Am J Pathol 155 1999 695 702
24. L. Obici, G. Franceschini, L. Calabresi, S. Giorgetti, M. Stoppini, and G. Merlini Structure, function and amyloidogenic propensity of apolipoprotein a-i Amyloid 13 2006 191 205
25. L. Obici, and G. Merlini AA amyloidosis: basic knowledge, unmet needs and future treatments Swiss Med Wkly 142 2012 w13580
26. J.D. Carroll, W.H. Gaasch, and K.P. McAdam Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation Am J Cardiol 49 1982 9 13
27. J. Koyama, P.A. Ray-Sequin, R. Davidoff, and R.H. Falk Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis Am J Cardiol 89 2002 1067 1071
28. J. Koyama, R. Davidoff, and R.H. Falk Longitudinal myocardial velocity gradient derived from pulsed doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction J Am Soc Echocardiogr 17 2004 36 44
29. D. Bellavia, T.P. Abraham, P.A. Pellikka, G.B. Al-Zahrani, A. Dispenzieri, and J.K. Oh Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography J Am Soc Echocardiogr 20 2007 1194 1202
30. J. Koyama, P.A. Ray-Sequin, and R.H. Falk Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis Circulation 107 2003 2446 2452
31. S. Ghio, S. Perlini, G. Palladini, N.A. Marsan, G. Faggiano, and M. Vezzoli Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis Eur J Heart Fail 9 2007 808 813
32. J.P. Sun, W.J. Stewart, X.S. Yang, R.O. Donnell, A.R. Leon, and J.M. Felner Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography Am J Cardiol 103 2009 411 415
33. G.B. Al-Zahrani, D. Bellavia, P.A. Pellikka, A. Dispenzieri, S.R. Hayman, and J.K. Oh Doppler myocardial imaging compared to standard 2-dimensional and doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis J Am Soc Echocardiogr 22 2009 290 298
34. S.J. Buss, M. Emami, D. Mereles, G. Korosoglou, A.V. Kristen, and A. Voss Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers J Am Coll Cardiol 60 2012 1067 1076
35. T. Oki, H. Tanaka, H. Yamada, T. Tabata, Y. Oishi, and T. Ishimoto Diagnosis of cardiac amyloidosis based on the myocardial velocity profile in the hypertrophied left ventricular wall Am J Cardiol 93 2004 864 869
36. A. Maceira, J. Joshi, S. Prasad, J. Moon, E. Perugini, and I. Harding Cardiovascular magnetic resonance in cardiac amyloidosis Circulation 111 2005 186 193
37. R. Kwong, and R. Falk Cardiovascular magnetic resonance in cardiac amyloidosis Circulation 111 2005 122 124
38. L. Thomson Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: diagnostic value of a typical pattern of late gadolinium enhancement J Am Coll Cardiol 51 2008 1031 1032
39. A. Mekinian, C. Lions, X. Leleu, A. Duhamel, N. Lamblin, and V. Coiteux Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging Am J Med 123 2010 864 868
40. H. Vogelsberg, H. Mahrholdt, C.C. Deluigi, A. Yilmaz, E.M. Kispert, and S. Greulich Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy J Am Coll Cardiol 51 2008 1022 1030
41. F.L. Ruberg, E. Appelbaum, R. Davidoff, A. Ozonoff, K.V. Kissinger, and C. Harrigan Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis Am J Cardiol 103 2009 544 549
42. I.S. Syed, J.F. Glockner, D. Feng, P.A. Araoz, M.W. Martinez, and W.D. Edwards Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis JACC Cardiovasc Imaging 3 2010 155 164
43. C. Rapezzi, G. Merlini, C. Quarta, L. Riva, S. Longhi, and O. Leone Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types Circulation 120 2009 1203 1212
44. E. Perugini, P. Guidalotti, F. Salvi, R. Cooke, C. Pettinato, and L. Riva Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mtc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy J Am Coll Cardiol 46 2005 1076 1084
45. C. Rapezzi, P. Guidalotti, F. Salvi, L. Riva, and E. Perugini Usefulness of 99mtc-dpd scintigraphy in cardiac amyloidosis J Am Coll Cardiol 51 2008 1509 1510 [author reply 1510]
46. C. Rapezzi, C.C. Quarta, P.L. Guidalotti, C. Pettinato, S. Fanti, and O. Leone Role of (99 m)tc-dpd scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis JACC Cardiovasc Imaging 4 2011 659 670
47. S. Bokhari, A. Castaño, T. Pozniakoff, S. Deslisle, and F. Latif Maurer MS: (99 m)tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses Circ Cardiovasc Imaging 6 2013 195 201
48. G. Merlini Cybord: stellar response rates in AL amyloidosis Blood 119 2012 4343 4345
49. G. Palladini, A. Foli, P. Milani, P. Russo, R. Albertini, and F. Lavatelli Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure Am J Hematol 87 2012 465 471
50. A. Dispenzieri, R. Kyle, M. Gertz, T. Therneau, W. Miller, and K. Chandrasekaran Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins Lancet 361 2003 1787 1789
51. A. Dispenzieri, M. Gertz, R. Kyle, M. Lacy, M. Burritt, and T. Therneau Serum cardiac troponins and n-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J Clin Oncol 22 2004 3751 3757
52. A.D. Wechalekar, S.O. Schonland, E. Kastritis, J.D. Gillmore, M.A. Dimopoulos, and T. Lane A European collaborative study of treatment outcomes in 346 patients with cardiac stage III Al amyloidosis Blood 121 2013 3420 3427
53. S. Kumar, A. Dispenzieri, M.Q. Lacy, S.R. Hayman, F.K. Buadi, and C. Colby Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements J Clin Oncol 30 2012 989 995
54. A. Kristen, E. Giannitsis, S. Lehrke, U. Hegenbart, M. Konstandin, and D. Lindenmaier Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin t assay Blood 116 2010 2455 2461
55. G. Palladini, A. Barassi, C. Klersy, R. Pacciolla, P. Milani, and G. Sarais The combination of high-sensitivity cardiac troponin t (hs-ctnt) at presentation and changes in n-terminal natriuretic peptide type b (nt-probnp) after chemotherapy best predicts survival in al amyloidosis Blood 116 2010 3426 3430
56. G. Palladini, A. Barassi, S. Perlini, P. Milani, A. Foli, and P. Russo Midregional proadrenomedullin (mr-proadm) is a powerful predictor of early death in al amyloidosis Amyloid 18 2011 216 221
57. G. Palladini, G. Malamani, F. Cò, A. Pistorio, F. Recusani, and E. Anesi Holter monitoring in al amyloidosis: prognostic implications Pacing Clin Electrophysiol 24 2001 1228 1233
58. S. Perlini, F. Salinaro, F. Cappelli, F. Perfetto, F. Bergesio, and A. Alogna Prognostic value of fragmented qrs in cardiac AL amyloidosis Int J Cardiol 167 2013 2156 2161
59. M. Boldrini, F. Salinaro, R. Mussinelli, A. Raimondi, A. Alogna, and F. Musca Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac al amyloidosis Ann Noninvasive Electrocardiol 18 2013 327 335
60. G. Gregorini, C. Izzi, L. Obici, R. Tardanico, C. Röcken, and B. Viola Renal apolipoprotein a-i amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis J Am Soc Nephrol 16 2005 3680 3686
61. J.H. Pinney, H.J. Lachmann, L. Bansi, A.D. Wechalekar, J.A. Gilbertson, and D. Rowczenio Outcome in renal AL amyloidosis after chemotherapy J Clin Oncol 29 2011 674 681
62. N. Leung, S.V. Glavey, S. Kumar, A. Dispenzieri, F.K. Buadi, and D. Dingli A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica 98 2013 988 992
63. H. Lachmann, H. Goodman, J. Gilbertson, J. Gallimore, C. Sabin, and J. Gillmore Natural history and outcome in systemic AA amyloidosis N Engl J Med 356 2007 2361 2371
64. M. Park, P. Mueller, R. Kyle, D. Larson, M. Plevak, and M. Gertz Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients Medicine (Baltimore) 82 2003 291 298
65. P. Russo, G. Palladini, A. Foli, L. Zenone Bragotti, P. Milani, and M. Nuvolone Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients Amyloid 18 2011 87 88
66. M. Gertz, R. Comenzo, R. Falk, J. Fermand, B. Hazenberg, and P. Hawkins Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18-22 April 2004 Am J Hematol 79 2005 319 328
67. J. Haan Amyloid and peripheral nervous system disease Clin Neurol Neurosurg 96 1994 332
68. L. Bernardi, C. Passino, C. Porta, E. Anesi, G. Palladini, and G. Merlini Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? Heart 88 2002 615 621
69. R. Caccialanza, G. Palladini, C. Klersy, H. Cena, C. Vagia, and B. Cameletti Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1 Am J Clin Nutr 83 2006 350 354
70. R. Caccialanza, G. Palladini, C. Klersy, E. Cereda, C. Bonardi, and B. Cameletti Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis Ann Hematol 91 2012 399 406
71. P.T. Sattianayagam, T. Lane, Z. Fox, A. Petrie, S.D. Gibbs, and J.H. Pinney A prospective study of nutritional status in immunoglobulin light chain amyloidosis Haematologica 98 2013 136 140
72. R. Caccialanza, G. Palladini, C. Klersy, E. Cereda, C. Bonardi, and L. Quarleri Serum prealbumin: an independent marker of short-term energy intake in the presence of multiple-organ disease involvement Nutrition 29 2013 580 582
73. O. Suhr, A. Danielsson, G. Holmgren, and L. Steen Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy J Intern Med 235 1994 479 485
74. G. Palladini, L. Verga, S. Corona, L. Obici, P. Morbini, and F. Lavatelli Diagnostic performance of immuno-electron microscopy of abdominal fat in systemic amyloidoses Amyloid 17 2010 59 60
75. E. Hachulla, A. Janin, R. Flipo, R. Saïle, T. Facon, and D. Bataille Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients Arthritis Rheum 36 1993 691 697
76. E. Lechapt-Zalcman, F.J. Authier, A. Creange, M.C. Voisin, and R.K. Gherardi Labial salivary gland biopsy for diagnosis of amyloid polyneuropathy Muscle Nerve 22 1999 105 107
77. A. Foli, G. Palladini, R. Caporali, L. Verga, P. Morbini, and L. Obici The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients Amyloid 18 2011 75 77
78. J. GAFNI, and E. SOHAR Rectal biopsy for the diagnosis of amyloidosis Am J Med Sci 240 1960 332 336
79. R.A. Kyle, R.J. Spencer, and D.C. Dahlin Value of rectal biopsy in the diagnosis of primary systemic amyloidosis Am J Med Sci 251 1966 501 506
80. H. Kobayashi, S. Tada, T. Fuchigami, Y. Okuda, K. Takasugi, and T. Matsumoto Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy Br J Rheumatol 35 1996 44 49
81. T. Kuroda, N. Tanabe, M. Sakatsume, S. Nozawa, T. Mitsuka, and H. Ishikawa Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis Clin Rheumatol 21 2002 123 128
82. C. Röcken, and K. Sletten Amyloid in surgical pathology Virchows Arch 443 2003 3 16
83. E. Anesi, G. Palladini, V. Perfetti, E. Arbustini, L. Obici, and G. Merlini Therapeutic advances demand accurate typing of amyloid deposits Am J Med 111 2001 243 244
84. H. Lachmann, D. Booth, S. Booth, A. Bybee, J. Gilbertson, and J. Gillmore Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis N Engl J Med 346 2002 1786 1791
85. G. Palladini, L. Obici, and G. Merlini Hereditary amyloidosis N Engl J Med 347 2002 1206 1207 [author reply 1206-1207]
86. A. Solomon, and P. Westermark Hereditary amyloidosis N Engl J Med 347 2002 1206 1207 [author reply 1206-1207]
87. R. Comenzo, P. Zhou, M. Fleisher, B. Clark, and J. Teruya-Feldstein Seeking confidence in the diagnosis of systemic AL (ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins Blood 107 2006 3489 3491
88. G. Palladini, and R.L. Comenzo The challenge of systemic immunoglobulin light-chain amyloidosis (al) Subcell Biochem 65 2012 609 642
89. A. Satoskar, K. Burdge, D. Cowden, G. Nadasdy, L. Hebert, and T. Nadasdy Typing of amyloidosis in renal biopsies: diagnostic pitfalls Arch Pathol Lab Med 131 2007 917 922
90. S.O. Schönland, U. Hegenbart, T. Bochtler, A. Mangatter, M. Hansberg, and A.D. Ho Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients Blood 119 2012 488 493
91. E. Arbustini, L. Verga, M. Concardi, G. Palladini, L. Obici, and G. Merlini Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis Amyloid 9 2002 108 114
92. F. Lavatelli, D. Perlman, B. Spencer, T. Prokaeva, M. McComb, and R. Théberge Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue Mol Cell Proteomics 7 2008 1570 1583
93. F. Lavatelli, V. Valentini, G. Palladini, L. Verga, P. Russo, and A. Foli Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits Amyloid 18 2011 59 61
94. J. Vrana, J. Gamez, B. Madden, J. Theis, H.r. Bergen, and A. Dogan Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens Blood 114 2009 4957 4959
95. F. Brambilla, F. Lavatelli, D. Di Silvestre, V. Valentini, R. Rossi, and G. Palladini Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue Blood 119 2012 1844 1847
96. H. Lachmann, R. Gallimore, J. Gillmore, H. Carr-Smith, A. Bradwell, and M. Pepys Outcome in systemic al amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy Br J Haematol 122 2003 78 84
97. R. Abraham, J. Katzmann, R. Clark, A. Bradwell, R. Kyle, and M. Gertz Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis Am J Clin Pathol 119 2003 274 278
98. H. Akar, D. Seldin, B. Magnani, C. O'Hara, J. Berk, and C. Schoonmaker Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis Amyloid 12 2005 210 215
99. J. Katzmann, R. Abraham, A. Dispenzieri, J. Lust, and R. Kyle Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice Clin Chem 51 2005 878 881
100. T. Bochtler, U. Hegenbart, C. Heiss, A. Benner, F. Cremer, and M. Volkmann Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis Haematologica 93 2008 459 462
101. G. Palladini, P. Russo, T. Bosoni, L. Verga, G. Sarais, and F. Lavatelli Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine Clin Chem 55 2009 499 504
102. V. Perfetti, M. Colli Vignarelli, E. Anesi, P. Garini, S. Quaglini, and E. Ascari The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients Haematologica 84 1999 218 221
103. J. Katzmann, R. Kyle, J. Benson, D. Larson, M. Snyder, and J. Lust Screening panels for detection of monoclonal gammopathies Clin Chem 55 2009 1517 1522
104. J. Katzmann Screening panels for monoclonal gammopathies: time to change Clin Biochem Rev 30 2009 105 111
105. G. Palladini, V. Perfetti, and G. Merlini Therapy and management of systemic AL (primary) amyloidosis Swiss Med Wkly 136 2006 715 720
106. A. Dispenzieri, M. Lacy, J. Katzmann, S. Rajkumar, R. Abraham, and S. Hayman Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood 107 2006 3378 3383
107. S.K. Kumar, A. Dispenzieri, M.Q. Lacy, S.R. Hayman, F.K. Buadi, and S.R. Zeldenrust Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis Am J Hematol 86 2011 251 255
108. G. Palladini, A. Dispenzieri, M.A. Gertz, S. Kumar, A. Wechalekar, and P.N. Hawkins New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes J Clin Oncol 30 2012 4541 4549
109. G. Merlini, D.C. Seldin, and M.A. Gertz Amyloidosis: pathogenesis and new therapeutic options J Clin Oncol 29 2011 1924 1933
110. G. Palladini, and G. Merlini Current treatment of AL amyloidosis Haematologica 94 2009 1044 1048
111. G. Palladini, R. Kyle, D. Larson, T. Therneau, G. Merlini, and M. Gertz Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis Amyloid 12 2005 120 126
112. G. Palladini, A. Dispenzieri, M.A. Gertz, S. Kumar, A. Wechalekar, and P.N. Hawkins New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes J Clin Oncol 30 2012 4541 4549
113. G. Palladini, and G. Merlini Transplantation vs. conventional-dose therapy for amyloidosis Curr Opin Oncol 23 2011 214 220
114. R.L. Comenzo, D. Reece, G. Palladini, D. Seldin, V. Sanchorawala, and H. Landau Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis Leukemia 26 2012 2317 2325
115. M.T. Cibeira, V. Sanchorawala, D.C. Seldin, K. Quillen, J.L. Berk, and L.M. Dember Outcome of al amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients Blood 118 2011 4346 4352
116. M.A. Gertz, M.Q. Lacy, A. Dispenzieri, S.K. Kumar, F.K. Buadi, and D. Dingli Trends in day 100 and 2-year survival after auto-sct for AL amyloidosis: outcomes before and after 2006 Bone Marrow Transplant 46 2011 970 975
117. A. Dispenzieri, M. Gertz, R. Kyle, M. Lacy, M. Burritt, and T. Therneau Prognostication of survival using cardiac troponins and n-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood 104 2004 1881 1887
118. M.A. Gertz, M.Q. Lacy, A. Dispenzieri, S.K. Kumar, D. Dingli, and N. Leung Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis Bone Marrow Transplant 48 2013 557 561
119. G. Palladini, V. Perfetti, L. Obici, R. Caccialanza, A. Semino, and F. Adami Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation Blood 103 2004 2936 2938
120. G. Palladini, P. Russo, M. Nuvolone, F. Lavatelli, V. Perfetti, and L. Obici Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis Blood 110 2007 787 788
121. A. Jaccard, P. Moreau, V. Leblond, X. Leleu, L. Benboubker, and O. Hermine High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 357 2007 1083 1093
122. A. Wechalekar, H. Goodman, H. Lachmann, M. Offer, P. Hawkins, and J. Gillmore Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis Blood 109 2007 457 464
123. R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 92 2007 1302 1307
124. G. Bianchi, L. Oliva, P. Cascio, N. Pengo, F. Fontana, and F. Cerruti The proteasome load vs. capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition Blood 113 2009 3040 3049
125. E. Kastritis, A. Wechalekar, M. Dimopoulos, G. Merlini, P. Hawkins, and V. Perfetti Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis J Clin Oncol 28 2010 1031 1037
126. D. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, G. Palladini, and J. Fermand Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study Blood 114 2009 1489 1497
127. S.W. Dubrey, D.E. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, and G. Palladini Group FTVCS: bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects QJM 104 2011 957 970
128. D.E. Reece, U. Hegenbart, V. Sanchorawala, G. Merlini, G. Palladini, and J. Bladé Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study Blood 118 2011 865 873
129. J.R. Mikhael, S.R. Schuster, V.H. Jimenez-Zepeda, N. Bello, J. Spong, and C.B. Reeder Cyclophosphamide-bortezomib-dexamethasone (cybord) produces rapid and complete hematologic response in patients with AL amyloidosis Blood 119 2012 4391 4394
130. C.P. Venner, T. Lane, D. Foard, L. Rannigan, S.D. Gibbs, and J.H. Pinney Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival Blood 119 2012 4387 4390
131. H. Landau, H. Hassoun, M.A. Rosenzweig, M. Maurer, J. Liu, and C. Flombaum Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis Leukemia 27 2013 823 828
132. G. Palladini, E. Anesi, V. Perfetti, L. Obici, R. Invernizzi, and C. Balduini A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis Br J Haematol 113 2001 1044 1046
133. M. Dhodapkar, M. Hussein, E. Rasmussen, A. Solomon, R. Larson, and J. Crowley Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) s9628 Blood 104 2004 3520 3526
134. D. Lebovic, J. Hoffman, B. Levine, H. Hassoun, H. Landau, and Y. Goldsmith Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone Br J Haematol 143 2008 369 373
135. S. Dietrich, S. Schönland, A. Benner, T. Bochtler, A. Kristen, and J. Beimler Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement Blood 116 2010 522 528
136. V. Sanchorawala, D.C. Seldin, J.L. Berk, J.M. Sloan, G. Doros, and M. Skinner Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis Clin Lymphoma Myeloma Leuk 10 2010 469 472
137. G. Palladini, P. Russo, F. Lavatelli, M. Nuvolone, R. Albertini, and T. Bosoni Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide Ann Hematol 88 2009 347 350
138. G. Palladini, V. Perfetti, S. Perlini, L. Obici, F. Lavatelli, and R. Caccialanza The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) Blood 105 2005 2949 2951
139. A. Dispenzieri, M. Lacy, S. Zeldenrust, S. Hayman, S. Kumar, and S. Geyer The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis Blood 109 2007 465 470
140. V. Sanchorawala, D. Wright, M. Rosenzweig, K. Finn, S. Fennessey, and J. Zeldis Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial Blood 109 2007 492 496
141. G. Palladini, P. Russo, A. Foli, P. Milani, F. Lavatelli, and L. Obici Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide Ann Hematol 91 2012 89 92
142. P. Moreau, A. Jaccard, L. Benboubker, B. Royer, X. Leleu, and F. Bridoux Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study Blood 116 2010 4777 4782
143. S.K. Kumar, S.R. Hayman, F.K. Buadi, V. Roy, M.Q. Lacy, and M.A. Gertz Lenalidomide, cyclophosphamide, and dexamethasone (crd) for light-chain amyloidosis: long-term results from a phase 2 trial Blood 119 2012 4860 4867
144. E. Kastritis, E. Terpos, M. Roussou, M. Gavriatopoulou, C. Pamboukas, and I. Boletis A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (rdc) in AL amyloidosis Blood 119 2012 5384 5390
145. G. Palladini, P. Russo, P. Milani, A. Foli, F. Lavatelli, and M. Nuvolone A phase ii trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis Haematologica 98 2013 433 436
146. V. Sanchorawala, J.M. Patel, J.M. Sloan, A.C. Shelton, J.B. Zeldis, and D.C. Seldin Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase ii trial Haematologica 98 2013 789 792
147. S. Dinner, W. Witteles, A. Afghahi, R. Witteles, S. Arai, and R. Lafayette Lenalidomide, melphalan and dexamethasone in an immunoglobulin light chain amyloidosis patient population with high rates of advanced cardiac involvement Haematologica 98 2013 1593 1599
148. A. Dispenzieri, F. Buadi, K. Laumann, B. LaPlant, S.R. Hayman, and S.K. Kumar Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis Blood 119 2012 5397 5404
149. G. Holmgren, L. Steen, J. Ekstedt, C.G. Groth, B.G. Ericzon, and S. Eriksson Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (fap-met30) Clin Genet 40 1991 242 246
150. G. Herlenius, H.E. Wilczek, M. Larsson, and B.G. Ericzon Registry FAPWT: ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry Transplantation 77 2004 64 71
151. D. Adams, D. Samuel, C. Goulon-Goeau, M. Nakazato, P.M. Costa, and C. Feray The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation Brain 123 2000 1495 1504
152. T. Kaido, A. Mori, F. Oike, M. Mizumoto, Y. Ogura, and K. Hata Impact of pretransplant nutritional status in patients undergoing liver transplantation Hepatogastroenterology 57 2010 1489 1492
153. P. Sharma, R.E. Perri, J.E. Sirven, S.R. Zeldenrust, D.J. Brandhagen, and C.B. Rosen Outcome of liver transplantation for familial amyloidotic polyneuropathy Liver Transpl 9 2003 1273 1280
154. A.J. Stangou, and P.N. Hawkins Liver transplantation in transthyretin-related familial amyloid polyneuropathy Curr Opin Neurol 17 2004 615 620
155. O.B. Suhr, G. Holmgren, L. Steen, L. Wikström, G. Norden, and S. Friman Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients Transplantation 60 1995 933 938
156. E.A. Pomfret, W.D. Lewis, R.L. Jenkins, P. Bergethon, S.W. Dubrey, and J. Reisinger Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy Transplantation 65 1998 918 925
157. B.O. Olofsson, C. Backman, K. Karp, and O.B. Suhr Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type Transplantation 73 2002 745 751
158. A. Stangou, P. Hawkins, N. Heaton, M. Rela, M. Monaghan, and P. Nihoyannopoulos Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis Transplantation 66 1998 229 233
159. J. Liepnieks, and M. Benson Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation Amyloid 14 2007 277 282
160. M. Yazaki, S. Mitsuhashi, T. Tokuda, F. Kametani, Y.I. Takei, and J. Koyama Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients Am J Transplant 7 2007 235 242
161. A.P. Barreiros, F. Post, M. Hoppe-Lotichius, R.P. Linke, C.F. Vahl, and H.J. Schäfers Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience Liver Transpl 16 2010 314 323
162. M. Munar-Qués, L. Salva-Ladaria, P. Mulet-Perera, M. Solé, F. López-Andreu, and M. Saraiva Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin Amyloid 7 2000 266 269
163. P. De Carolis, M. Galeotti, G. Ficarra, M. Masetti, D. Grimaldi, and P. Cortelli Fatal cerebral haemorrhage after liver transplantation in a patient with transthyretin variant (gly53glu) amyloidosis Neurol Sci 27 2006 352 354
164. A. Stangou, N. Heaton, and P. Hawkins Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation N Engl J Med 352 2005 2356
165. A.P. Barreiros, C. Geber, F. Birklein, P.R. Galle, and G. Otto Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation Liver Transpl 16 2010 109
166. T. Coelho, D. Adams, A. Silva, P. Lozeron, P.N. Hawkins, and T. Mant Safety and efficacy of RNAi therapy for transthyretin amyloidosis N Engl J Med 369 2013 819 829
167. J. Gillmore, L. Lovat, M. Persey, M. Pepys, and P. Hawkins Amyloid load and clinical outcome in aa amyloidosis in relation to circulating concentration of serum amyloid a protein Lancet 358 2001 24 29
168. T. Nakamura Amyloid a amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments Clin Exp Rheumatol 29 2011 850 857
169. A. Fernández-Nebro, A. Olivé, M.C. Castro, A.H. Varela, E. Riera, and M.V. Irigoyen Long-term tnf-alpha blockade in patients with amyloid a amyloidosis complicating rheumatic diseases Am J Med 123 2010 454 461
170. H.J. Lachmann, P. Quartier, A. So, and P.N. Hawkins The emerging role of interleukin-1β in autoinflammatory diseases Arthritis Rheum 63 2011 314 324
171. G. Merlini, E. Ascari, N. Amboldi, V. Bellotti, E. Arbustini, and V. Perfetti Interaction of the anthracycline 4′-iodo-4′- deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis Proc Natl Acad Sci U S A 92 1995 2959 2963
172. L. Gianni, V. Bellotti, A.M. Gianni, and G. Merlini New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo-4′- deoxydoxorubicin Blood 86 1995 855 861
173. J.A. Palha, D. Ballinari, N. Amboldi, I. Cardoso, R. Fernandes, and V. Bellotti 4′-iodo-4′-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid Am J Pathol 156 2000 1919 1925
174. M.P. Sebastião, G. Merlini, M.J. Saraiva, and A.M. Damas The molecular interaction of 4′-iodo-4′-deoxydoxorubicin with leu-55pro transthyretin 'amyloid-like' oligomer leading to disaggregation Biochem J 351 2000 273 279
175. I. Cardoso, G. Merlini, and M.J. Saraiva 4′-iodo-4′- deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters FASEB J 17 2003 803 809
176. I. Cardoso, and M.J. Saraiva Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model FASEB J 20 2006 234 239
177. I. Cardoso, D. Martins, T. Ribeiro, G. Merlini, and M.J. Saraiva Synergy of combined doxycycline/tudca treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models J Transl Med 8 2010 74
178. L. Obici, A. Cortese, A. Lozza, J. Lucchetti, M. Gobbi, and G. Palladini Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study Amyloid 19 2012 34 36
179. N. Ferreira, M.J. Saraiva, and M.R. Almeida Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation FEBS Lett 585 2011 2424 2430
180. N. Ferreira, M.J. Saraiva, and M.R. Almeida Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy Amyloid 19 2012 39 42
181. K. Rezai-Zadeh, D. Shytle, N. Sun, T. Mori, H. Hou, and D. Jeanniton Green tea epigallocatechin-3-gallate (egcg) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer's transgenic mice J Neurosci 25 2005 8807 8814
182. D.E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst, L. Masino, and R. Lurz Egcg redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat Struct Mol Biol 15 2008 558 566
183. N. Ferreira, I. Cardoso, M.R. Domingues, R. Vitorino, M. Bastos, and G. Bai Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity FEBS Lett 583 2009 3569 3576
184. W. Hunstein Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110 2007 2216
185. D. Mereles, S.J. Buss, S.E. Hardt, W. Hunstein, and H.A. Katus Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis Clin Res Cardiol 99 2010 483 490
186. A.V. Kristen, S. Lehrke, S. Buss, D. Mereles, H. Steen, and P. Ehlermann Green tea halts progression of cardiac transthyretin amyloidosis: an observational report Clin Res Cardiol 101 2012 805 813
187. N. Ferreira, M.J. Saraiva, and M.R. Almeida Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models PLoS One 7 2012 e29933
188. M.B. Pepys, J. Herbert, W.L. Hutchinson, G.A. Tennent, H.J. Lachmann, and J.R. Gallimore Targeted pharmacological depletion of serum amyloid p component for treatment of human amyloidosis Nature 417 2002 254 259
189. J.D. Gillmore, G.A. Tennent, W.L. Hutchinson, J.R. Gallimore, H.J. Lachmann, and H.J. Goodman Sustained pharmacological depletion of serum amyloid p component in patients with systemic amyloidosis Br J Haematol 148 2010 760 767
190. K. Bodin, S. Ellmerich, M.C. Kahan, G.A. Tennent, A. Loesch, and J.A. Gilbertson Antibodies to human serum amyloid p component eliminate visceral amyloid deposits Nature 468 2010 93 97
191. R. Hrncic, J. Wall, D. Wolfenbarger, C. Murphy, M. Schell, and D. Weiss Antibody-mediated resolution of light chain-associated amyloid deposits Am J Pathol 157 2000 1239 1246
192. A. Solomon, D.T. Weiss, and J.S. Wall Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1f4 Clin Cancer Res 9 2003 3831S 3838S
193. J.L. Berk, O.B. Suhr, Y. Sekijima, T. Yamashita, M. Heneghan, and S.R. Zeldenrust The diflunisal trial: study accrual and drug tolerance Amyloid 19 2012 37 38
194. A. Castaño, S. Helmke, J. Alvarez, S. Delisle, and M.S. Maurer Diflunisal for ATTR cardiac amyloidosis Congest Heart Fail 18 2012 315 319
195. T. Coelho, L.F. Maia, A. Martins da Silva, M. Waddington Cruz, V. Plante-Bordeneuve, and P. Lozeron Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial Neurology 79 2012 785 792
196. R. Kisilevsky, L. Lemieux, P. Fraser, X. Kong, P. Hultin, and W. Szarek Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease Nat Med 1 1995 143 148
197. L. Dember, P. Hawkins, B. Hazenberg, P. Gorevic, G. Merlini, and I. Butrimiene Eprodisate for the treatment of renal disease in AA amyloidosis N Engl J Med 356 2007 2349 2360
198. A. Kristen, T. Dengler, U. Hegenbart, S. Schonland, H. Goldschmidt, and F. Sack Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death Heart Rhythm 5 2008 235 240
199. L. Yam, and S. Oropilla Octreotide for diarrhea in amyloidosis Ann Intern Med 115 1991 577
200. Y.S. Jeong, J.B. Jun, T.H. Kim, I.H. Lee, S.C. Bae, and D.H. Yoo Successful treatment of protein-losing enteropathy due to aa amyloidosis with somatostatin analogue and high dose steroid in ankylosing spondylitis Clin Exp Rheumatol 18 2000 619 621
201. T. Fushimi, Y. Takahashi, Y. Kashima, K. Fukushima, W. Ishii, and K. Kaneko Severe protein losing enteropathy with intractable diarrhea due to systemic aa amyloidosis, successfully treated with corticosteroid and octreotide Amyloid 12 2005 48 53
202. J.K. Shin, Y.H. Jung, M.N. Bae, I.W. Baek, K.J. Kim, and C.S. Cho Successful treatment of protein-losing enteropathy due to AA amyloidosis with octreotide in a patient with rheumatoid arthritis Mod Rheumatol 23 2013 406 411
203. P.T. Sattianayagam, T. Lane, Z. Fox, A. Petrie, S.D. Gibbs, and J.H. Pinney A prospective study of nutritional status in AL amyloidosis Haematologica 98 2013 136 140
204. T. Ueno, K. Takeda, and M. Nagata Remission of proteinuria and preservation of renal function in patients with renal aa amyloidosis secondary to rheumatoid arthritis Nephrol Dial Transplant 27 2012 633 639
205. T. Bansal, A. Garg, J.A. Snowden, and W. McKane Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias Nephron Clin Pract 120 2012 c228 c235
206. J. Gillmore, H. Goodman, H. Lachmann, M. Offer, A. Wechalekar, and J. Joshi Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis Blood 107 2006 1227 1229
207. M. Maurer, A. Raina, C. Hesdorffer, R. Bijou, P. Colombo, and M. Deng Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure Transplantation 83 2007 539 545
208. F. Sack, A. Kristen, H. Goldschmidt, P. Schnabel, T. Dengler, and A. Koch Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with al-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis Eur J Cardiothorac Surg 33 2008 257 262
209. M.Q. Lacy, A. Dispenzieri, S.R. Hayman, S. Kumar, R.A. Kyle, and S.V. Rajkumar Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy J Heart Lung Transplant 27 2008 823 829
210. B. Dey, S. Chung, T. Spitzer, H. Zheng, T. Macgillivray, and D. Seldin Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure Transplantation 90 2010 905 911
211. P.T. Sattianayagam, S.D. Gibbs, J.H. Pinney, A.D. Wechalekar, H.J. Lachmann, and C.J. Whelan Solid organ transplantation in AL amyloidosis Am J Transplant 10 2010 2124 2131
212. P.L. Swiecicki, B.S. Edwards, S.S. Kushwaha, A. Dispenzieri, S.J. Park, and M.A. Gertz Left ventricular device implantation for advanced cardiac amyloidosis J Heart Lung Transplant 32 2013 563 568
213. T. Kofman, P. Grimbert, F. Canouï-Poitrine, J. Zuber, V. Garrigue, and C. Mousson Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study Am J Transplant 11 2011 2423 2431
214. J. Gillmore, A. Stangou, G. Tennent, D. Booth, J. O'Grady, and M. Rela Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein Ai Gly26Arg Transplantation 71 2001 986 992